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Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) is a highly infectious
viral syndrome currently threateningmillions of peopleworldwide. It iswidely recognized as a disease of the pul-
monary system, presenting with fever, cough, and shortness of breath. However, a number of extrapulmonary
manifestations have been described in the literature.
Objective: In this review, we seek to provide a comprehensive summary of the hematologic, gastroenterological,
renal, dermatologic, neurologic, and psychiatric manifestations of COVID-19.
Discussion:HematologicalpresentationsofCOVID-19 include laboratoryabnormalities suchasdecreasedtotal lym-
phocyte count, prolonged prothrombin time (PT), elevated d-dimer, and increased lactate dehydrogenase (LDH).
Several of these findings are associatedwith increasedmortality among infected patients. Themost common gas-
trointestinal symptoms include nausea, vomiting, diarrhea, and abdominal pain. Furthermore, presence of viral
RNA in patient stool suggests the possibility of additional testingmodalities for COVID-19. Nephrological findings
such as proteinuria, hematuria, and elevated BUN and creatinine levels have been observed. Additionally, several
studies demonstrated that patients with COVID-19who developed acute kidney injury (AKI) had a greater risk of
mortality. The virus canalsopresentwith cutaneous symptomssuchas erythematous rashes, urticaria, and chicken
pox-like lesions.Neuropsychiatricsymptomshavebeendescribed inthe literature,andpatientscanexhibitfindings
consistent with viral encephalitis, cerebral vascular disease, peripheral nerve disorders, and psychosis.
Conclusion: Although COVID-19 does usually present primarily with respiratory symptoms, the extra-pulmonary
manifestations of the virus are unpredictable and varied. Better understanding and awareness of these symptoms
can lead to more efficient diagnosis, rapid treatment, isolation, and decreased spread of the disease.
© 2020 Elsevier Inc. All rights reserved.
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1. Introduction
On December 31st, 2019, the city of Wuhan, China first reported
cases of a novel virus that was causing severe pulmonary symptoms
and deaths [1]. FromDecember to February, SARS-CoV-2 quickly spread
to other provinces in China and Europe. This viruswas taxonomically re-
lated to the SARS-CoV and Middle East respiratory syndrome coronavi-
rus (MERS-CoV), and it similarly originated in a non-human host (most
likely bat) [2]. To date, the SARS-CoV-2 virus has had devastating effects
on human life, healthcare systems, and economies.
SARS-CoV-2 is a beta-coronavirus that has, as of June 2020, infected
over 7 million people and resulted in more than 400,000 deaths world-
wide. COVID-19 typically presents with pulmonary symptoms such as
cough and sore throat and can progress to pneumonia, bronchitis, and
acute respiratory distress syndrome (ARDS). While the respiratory
spread of COVID-19 has been well documented in the literature, further
case reports have shown that the virus is not confined to just the lung.
SARS-CoV-2 utilizes a spike protein to attach to the host ACE2 receptor,
which is found in several organ systems [2]. Upon entering the cell, the
virus initiates an immune cascade,which stimulates immune cells, lead-
ing to a cytokine storm and eventual destruction of tissues [3]. Its pri-
mary mode of transmission is through inhalation, though studies have
suggested potential alternative means of spread.
Much has been documented in the literature regarding the respira-
tory presentations of the virus, but the extrapulmonary manifestations
need further investigation. In this article, we review research on the he-
matological, gastrointestinal, renal, dermatologic, neurologic, and psy-
chiatric complications of COVID-19.
2. Methods
The authors searched PubMed, Google Scholar, medRxiv, and
SCOPUS for articles using a combination of the keywords “COVID-19,”
“SARS-CoV-2,” and “hematology”, “Neurology”, “gastrointestinal”, “psy-
chiatry”, “dermatology”, “renal”. This narrative review summarizes the
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extrapulmonary manifestations of COVID-19 and addresses key points
regarding multiorgan involvement. All types of studies were evaluated
including systematic reviews, case reports, case-studies, retrospective
and prospective studies, letters, perspective, commentaries, and clinical
guidelines. The references of all included studies were also reviewed to
identify additional sources. Only studies in English (including translated
studies) were reviewed. The initial literature search identified 1653 ar-
ticles, of which 151 articles were deemed relevant to our research ques-




Several studies have shown that patients infected with COVID-19
share similar laboratory abnormalities including decreased total lym-
phocyte count, prolonged prothrombin time, elevated d-dimer levels
and increased lactate dehydrogenase (LDH) [2-8]. A recent meta-
analysis of the laboratory derangements in COVID-19 demonstrated
that lymphopenia (35–75% of cases), increased LDH (27–92% of cases),
elevated and d-dimer (36–43% of cases) were among themost frequent
findings [9].
3.1.1. Lab abnormalities and severity of disease
Patients with significant lab derangements had more severe disease
and a greater need for critical care [2,3,5,6,9-12]. Lymphopenia is often
more pronounced in those requiring ICU level care [11-15]. In
Singapore, Fan et al. noted that 28% of patients infected with COVID-
19 had lymphopenia, with critical care patients demonstrating signifi-
cantly decreased lymphocytes compared with those not requiring ICU
treatment [14]. Furthermore, 4 of the 9 ICU patients also exhibited in-
creased levels of LDH (median value of 1684 U/L) compared to the
non-ICU patients where only 5 of 26 had moderately elevated LDH
[14]. Huang et al. demonstrated that in addition to marked lymphope-
nia, patients needing intensive care had higher levels of d-dimer (level
2.4 mg/L [0.6–14.4]) on admission than those who did not require it
(0.5 mg/L [0.3–0.8], p = 0.0042) and also higher prothrombin times
12.2 s [IQR 11.2–13.4] when compared with non-ICU patients (10.7 s
[9.8–12.1], p=0·012) [3]. In a study of 140 COVID-19 positive patients
by Zhang et al., 58 patients who were considered to have “severe dis-
ease” demonstrated a 2-fold increase in d-dimer compared to those
with mild disease [16]. Guan et al. also determined that a significant
elevation in d-dimer was more pronounced in severe cases (59.6%
vs. 43.2% in non-severe) [5].
A meta-analysis examining the role of laboratory abnormalities in
patients with severe COVID-19 vs. those with milder disease deter-
mined that the most predictive parameters of critical infection were
lymphopenia (96.1% vs. 80.4%), thrombocytopenia (57.7% vs. 31.6%), in-
creased LDH (58.1% vs. 37.2%) and elevated d-dimer (59.6% vs. 43.2%)
[9]. Specifically, in Wu et al.'s retrospective analysis of the risk factors
for disease progression to ARDS, they observed a statistically significant
association between lymphopenia and the development of ARDS
(P < 0.001) [8]. Several studies also established that higher CRP levels
correlatedwith worse outcomes in COVID-19 such as ARDS, myocardial
injury, and death [8,15,17]. As such, tracking hematologic parameters is
crucial in determining prognosis and management, particularly with
regard to level of care and monitoring.
3.1.2. Lab abnormalities and mortality
In addition to indicating the potential for more severe disease, labo-
ratory abnormalities are also a predictor ofmortality in infected patients
[2,13]. In a case series of 138 patients with COVID-19, the mortality rate
was about 4.3% (6 patients). Of those 6, 5 patients had persistent lab de-
rangements including increased d-dimer and decreased lymphocyte
counts [2]. Another retrospective cohort showed that elevated
d-dimer was associated with a higher rate of in-hospital death with
81% of terminal cases exhibiting d-dimer>1 μg [13]. Tang et al. analyzed
abnormal coagulation parameters in patients with SARS-CoV-2 pneu-
monia and determined that non-survivors had significantly higher
d-dimer, fibrin degradation products (FDP), and prothrombin time on
admission compared to survivors (P<0.05) [18]. This studywas further
supported by Han et al. who also demonstrated that d-dimer and FDP
were especially predictive of disease progression [19]. A recent report
investigating the factors affecting 28-day mortality of patients with se-
vere illness showed that elevated d-dimer, increased age, and prolonged
PT were associated with a higher mortality [20]. Early recognition of
these abnormal results will play a critical role in predicting disease se-
verity and improving outcomes with earlier intervention and support-
ive therapy.
3.1.3. COVID-19 and coagulopathy
Coagulation parameters are often cited as indicators for worse prog-
nosis in patients infected with COVID-19 [17,19,21]. Compared to a
healthy control, d-dimer, FDP, and fibrinogen levels are all increased
in COVID-19 patients, while antithrombin (AT) levels are significantly
reduced [19]. Emerging data suggests that deregulated thrombin gener-
ation and abnormal activation of the coagulation cascade can lead to the
development of disseminated intravascular coagulation (DIC) and is as-
sociated with worsening pneumonia and mortality [7,22-24]. DIC was a
significantly more common finding in non-survivors (71.4%) vs. survi-
vors (0.6%) [18]. Other manifestations of coagulopathy such as the de-
velopment of antiphospholipid antibodies and subsequent thrombotic
events were reported in 3 ICU patients infected with SARS-CoV-2 in
Wuhan, China [25]. Due to coagulation abnormalities, COVID-19 pa-
tients are at a higher risk of VTE, especially those with pre-existing co-
morbidities [23]. Early monitoring of these parameters can help guide
medical management such as the use of VTE prophylaxis and escalation
of care.
A study of COVID-19 patients from the First Affiliated Hospital of
Zhengshou University, Henan, China demonstrated that infected pa-
tients have an overall pro-thrombotic state due to platelet hyperactivity
[26]. When SARS-CoV-2 and its spike protein bind directly to the plate-
let and ACE2 receptor, there is increased platelet activation and throm-
bus formation due to activation of the MAPK pathway. This facilitates
the release of coagulation and inflammatory factors, leading to an over-
all pro-thrombotic and pro-inflammatory state [26]. The authors also
suggest that the addition of ACE2 protein and anti-Spike neutralizing
antibodies may be a therapeutic approach to avoid thrombotic events
in these patients.
3.2. Cardiovascular symptoms
Patients with critical COVID-19 infection can also present with vari-
ous cardiovascular symptoms. Animal models and cardiac autopsies
suggest that COVID-19 can infect the cardiac tissue by binding to the
angiotensin-converting enzyme (ACE) receptors, which can result in
myocardial inflammation and damage [27]. Among the reported cardiac
manifestations of COVID-19 are myocardial injury, myocarditis,
arrythmias, cardiomyopathy, and heart failure. These symptoms are
summarized in Table 1.
3.2.1. Myocardial injury and myocarditis
Myocardial injury is defined as an elevation in biomarkers such as
cardiac troponin I. Acute myocardial injury was reported in some of
the earliest cases of COVID-19 in Wuhan, China. An early 2019 study
among 41 admitted hospital patients in Wuhan reported acute cardiac
injury in 12% of the patients [3]. Furthermore, another study of 138 hos-
pitalized patients in Wuhan reported that as high as 22% of those who
required ICU care experienced acute myocardial injury [2]. Another ret-
rospective, observational study of 52 critically ill patients in Wuhan,
China reported cardiac injury in 23% of the patients [28]. The increased
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prevalence of cardiac injury amongpatientswith COVID-19 could be ex-
plained by the significantly higher levels of cardiac troponin I in severely
ill patients [29].
A recent multi-hospital retrospective cohort of nearly 3000 patients
demonstrated that myocardial injury was common among hospitalized
COVID-19 patients (n=985, 36%), and that those with a history of car-
diovascular disease (CVD) were more likely to experience myocardial
injury than those without [30]. Similarly, A study of 44,672 patients
with COVID-19 demonstrated that a history of CVD was associated
with a five-fold increase in case fatality rate compared to those without
CVD (10.5% VS. 2.3%) [31,32].
A study by Lala, et al., showed that mild myocardial injury as evi-
denced by small increases in troponin was significantly associated
with death (adjusted hazard ratio: 1.75; 95% CI: 1.37 to 2.24;
p < 0.001), and that greater elevations correlated with a higher risk of
mortality (adjusted HR: 3.03; 95% CI: 2.42 to 3.80; p< 0.001) [30]. Sim-
ilarly, a single center retrospective study of 50 COVID-19 ICU patients in
Turkey demonstrated that cardiac biomarkers including troponin I and
NT-proBNP were higher in non-survivors compared to survivors [33].
Myocarditis has also contributed to mortality associated with
COVID-19. In a case series of 150 patients, researchers determined
that 7% died frommyocarditis with circulatory failure [34]. Clinically, di-
agnosing myocarditis can be challenging, especially when differentiat-
ing it from acute coronary syndrome. For this reason, echocardiogram
evaluation is recommended, and myocarditis associated with COVID-
19will appear as globalwall motion dysfunctionwithout focal wall mo-
tion defects [31,35,36]. Additionally, ECG abnormalities may occur as a
result of myocardial inflammation, such as T wave inversion, PR and
ST segment deviations [31]. Autopsy reports of COVID-19 patients
have reported high viral loads, mononuclear cells, and lymphocytic
infiltration as key players in mediating acute myocarditis [37-39].
3.2.2. Arrythmias
A wide variety of arrythmias have been observed in patients with
COVID-19. In a study of 137 patients in Hubei Province, 7.3% of patients
reported heart palpitations [40]. In another report of 138 hospitalized
patients, cardiac arrythmia was noted in 16.7%, and these arrythmias
were more common in ICU patients [2]. In a much larger study of 700
patients, 9 cardiac arrests, 25 atrial fibrillation events, 9 clinically signif-
icant bradyarrhythmias, and 10 non-sustained ventricular tachycardias
were reported [41]. Additionally, this study noted that ICU admissions
were associatedwith incidents of atrialfibrillation among COVID-19 pa-
tients, indicating that these arrythmias can contribute to severity of ill-
ness [41]. Lastly, a retrospective case series published in Cureus
discussed COVID-19 related prolonged QTc and transient bradycardia
as manifestations of the illness [42].
Many etiologies have been proposed to explain the occurrence of
arrythmias among COVID-19 patients. Hypoxia, inflammatory damage,
abnormal metabolism, neurohormonal stress, and response to medica-
tions are some of the likely etiologies [31,35,42]. Furthermore, the effect
of pro-inflammatory cytokines on the sinoatrial node could lead to the
development of bradycardia in patients with COVID-19 [42].
3.2.3. Cardiomyopathy and heart failure
In a retrospective cohort study of COVID-19 patients in Wuhan,
China, Zhou et al. reported heart failure in 23% of admitted pa-
tients [13]. This number was as high as 52% in those who did
not survive the infection [13]. Another retrospective study dem-
onstrated that heart failure and acute cardiac injury were more
common in deceased patients, regardless of their cardiovascular
history [43]. Specifically, this study reported heart failure in 24%
of deceased patients, nearly half of whom did not have any history
of cardiovascular disease or hypertension [43]. It is unclear
whether the heart failure was due to a new cardiomyopathy or
an exacerbation of existing undiagnosed left ventricular dysfunc-
tion, and the etiology is still being investigated [31,35]. Addition-
ally, right heart failure can occur in patients with severe lung
injury and ARDS [31,35]. As such, physicians should be cautious
of underlying cardiac dysfunction when administering IV fluids
[31,35].
Several recent case reports have also highlighted the development of
Takotsubo Syndrome (TTS) in those infected with COVID-19 [44-47].
One report detailed the case of a patient who developed cardiogenic
shock 16 days after infection despite normal initial troponin levels and
LVEF [44]. Her bedside echo demonstrated the apical ballooning typical
of TTS. Similarly, another case report discussed the case of a previously
healthy 50years oldmalewho developed chest pain and signs of cardio-
genic shock 8 days after the onset of symptoms. His echocardiogram
showed akinesia of all of his basal segments, and he was ultimately
diagnosed with inverted Takotsubo cardiomyopathy [45].
3.3. Gastrointestinal symptoms
While the most fatal complications of COVID-19 include ARDS,
heart failure, renal failure, liver injury, and multiple organ dysfunc-
tion syndrome (MODS), GI symptoms can contribute significantly to
morbidity in infected patients [48]. With regard to the gastrointes-
tinal system, SARS-CoV-2 can present with nausea, vomiting, diar-
rhea, and/or abdominal discomfort [3,49-53]. A cross-sectional
analysis of 204 Chinese patients with COVID-19 demonstrated that
over half (103 patients, 50.5%) reported experiencing at least one
of the GI symptoms. Among those, 78.6% expressed loss of appetite,
34% complained of diarrhea, 3.9% reported vomiting, and 1.9% indi-
cated they had abdominal pain [54]. Similar clinical studies among
COVID-19 patients have observed diarrhea in 3% to 61% of patients,
nausea in 10% to 58%, and vomiting in 2% to 5%. Other gastrointesti-
nal symptoms included epigastric pain, belching, and anorexia
[16,55-58] (summarized in Table 2).
Healthcare workers can easily be overwhelmed by the complex
symptomology and acuity of cases. While focusing primarily on the
most critical respiratory symptoms, gastrointestinal manifestations
can be overlooked. Though GI symptoms are not prominent in most
cases and are unlikely life-threatening on their own, clinicians should
endeavor to identify these early symptoms in order to prevent the po-
tential spread of COVID-19.
Table 1
Studies with COVID-19 patients presenting with cardiac symptoms.
Authors Publication year Type of study Number of patients Cardiac symptoms (%)
Yang et al. [28] 2020 Retrospective 52 Chest pain (2%), cardiac injury (23%)
Lippi et al. [29] 2020 Meta-analysis 341 Cardiac injury
Huang et al. [3] 2020 Retrospective 41 Cardiac injury (12%)
Ruan et al. [34] 2020 Retrospective 150 Myocardial damage (7%)
Liu, et al. [40] 2020 Retrospective 137 Heart palpitation (7.3%),
Wang, et al. [2] 2020 Retrospective 138 Acute cardiac injury (7.2%), Arrythmia (16.7%)
Bhatla, et al. [41] 2020 Retrospective 700 Cardiac arrest (1.3%), Atrial fibrillation (3.6%), Bradycardia (1.3%), Non-sustained
ventricular tachycardia (1.4%)
Amaratunga, et al. [42] 2020 Retrospective case series 4 Bradycardia (75%), Prolonged QTc (25%)
Zhou, et al. [13] 2020 Retrospective 191 Coronary heart disease (8%), Heart failure (23%), Acute cardiac injury (17%)
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3.3.1. GI symptoms and disease severity
Some studies have shown that GI symptoms can manifest be-
fore the onset of typical respiratory symptoms [2,59]. The first con-
firmed case of COVID-19 in the US presented with a two-day
history of nausea without respiratory complaint. Days into the ill-
ness, the patient also complained of abdominal discomfort and
loose stools [60]. Similarly, a recent report described a COVID-19
patient presenting with diarrhea, borborygmus, anorexia, and nau-
sea in the absence of any respiratory symptoms [61]. Early re-
search has suggested a correlation between GI symptoms and
severity of illness. Henry et al. performed a pooled analysis of 10
different studies with a total sample of 1989 COVID-19 patients,
598 of whom (30.1%) were deemed as having “severe disease.”
This study examined whether patients presenting with GI symp-
toms could be at an increased risk of critical illness and poor prog-
nosis. The research highlighted a significant association between
abdominal pain and illness severity. Furthermore, nausea and
vomiting correlated with a marginally increased risk of severe
COVID-19, while diarrhea was not reported to be associated with
worse disease [62]. Another retrospective case-controlled study
of 278 COVID-19 positive patients and 238 COVID-19 negative
patients suggested that patients presenting with GI symptoms at
time of testing were more likely to test positive for the virus
[63]. In comparison, patients without GI symptoms were equally
likely to test positive or negative for COVID-19 [63]. Lastly, in the
past few months, two cases of paralytic ileus were reported
among COVID-19 patients [64]. Histopathology of resected bowel
specimen in these cases suggests a role for COVID-19-induced
micro-thrombosis leading to GI perforation [64].
3.3.2. Fecal shedding of COVID-19
In addition to research showing the potential correlation between GI
symptoms and disease severity, several studies have determined that
infected patients can shed viral particles in their stool [65-67]. One
study of 42 COVID-19 positive patients demonstrated that about 67%
of the patients had viral RNA present in their stool even in the absence
of diarrhea or other GI symptoms. Interestingly, among this group,
64% of the patients continued to shed viral particles in fecal specimens
even after the nasopharyngeal swabs turned negative [65]. This has
been documented in both adult and pediatric patients. Xu et al. con-
ducted an epidemiological and clinical study of 10 children with
COVID-19 and found that 8 persistently tested positive in stool despite
their nasopharyngeal swabs being negative [68].
Fecal specimen testing is just as accurate in detecting COVID-19 as
nasopharyngeal swabs [66,69]. Physiologically, the presence of viral
particles in feces is plausible as there is a high level of viral receptor an-
giotensin converting enzyme 2 (ACE2) in the gastrointestinal tract [70].
While the current research is not definitive, studies have indicated that
asymptomatic patients may shed COVID-19 viral particles in their stool
[66,71-74].Whether these particles are infectious and support the argu-
ment for possible the fecal-oral transmission of SARS-CoV-2 remains
unclear.
3.3.3. Endoscopies
Several studies have examined whether GI procedures such as en-
doscopies can safely be performed on COVID-19 positive patients. A
study conducted in northern Italy identified 23 COVID-19 patients pre-
senting with signs of upper GI bleeding, therefore necessitating urgent
endoscopy [75]. The virus has been detected in biopsies of the esopha-
gus, stomach, duodenum, and rectum [76]. Since endoscopes are in con-
tact with mucus membrane and body fluids, it is possible that these
instruments can be implicated in transmission the virus [77]. As such,
most guidelines recommend the use of personal protective equipment
(PPE) during endoscopic examination in order to prevent nosocomial
outbreaks of COVID-19 [78-81]. When the virus is highly suspected or
confirmed, double gloves and N95 or FFP2/3 masks are indicated and
the operative team should be properly trained to wear and remove
PPE safely [79].
3.4. Renal symptoms
SARS-CoV-2 can have a profound impact on the renal system. Early
research has determined that COVID-19 can directly infect kidney tu-
bules and cause acute tubular damage and subsequent renal failure
[82,83]. An analysis of kidney findings at autopsy of 26 COVID-19 posi-
tive patients in Wuhan showed tubular injury and direct viral infiltra-
tion of the tubular epithelium [84,85]. Data also suggests that renal
dysfunctionmay bemultifactorial due to cytokine storm, hemodynamic
changes, direct viral toxicity, or thromboticmicroangiopathy [86]. Renal
deterioration has been associated with a 5.3-fold increased mortality in
COVID-19 patients. Often these patients demonstrate radiographic evi-
dence of kidney dysfunction, such as renal interstitial inflammation
and edema on CT [87]. A recent published report detailed the case of
an African American male patient who presented with acute kidney in-
jury due to collapsing glomerulopathy in the context of a COVID-19 in-
fection without any signs of respiratory disease, indicating that renal
manifestations of COVID-19 are possible even in patients with other-
wise mild symptoms [85].
3.4.1. Renal laboratory abnormalities & disease severity
While research suggests that advanced age, organ failure, and ele-
vated d-dimer levels are indicators of poor prognosis in COVID-19 pa-
tients, a recent study highlights kidney dysfunction as a potential risk
factor for mortality, as well [13,87]. A multi-center retrospective study
of 193 COVID-19 patients (128 with non-severe disease, 65 severe) in-
vestigated the presence of kidney dysfunction and demonstrated that,
on admission, 59% of patients had proteinuria, 44% had hematuria,
14% had elevated BUN, and 10% had elevated creatinine levels [87].
These lab derangements were found to be significantly worse in those
with critical illness (including non-survivors), and 66% of the patients
who developed an AKI (43/65) were considered to have severe disease
[87]. Per Pei at el., 75.4% of patients with COVID-19 had an abnormal
urine dipstick at initial presentation [88]. These findings have been
reproduced by several other studies which have shown that develop-
ment of an AKI is a common lab finding in COVID-19 and a feature of
Table 2
Studies with COVID-19 patients presenting with GI symptoms.
Authors Publication year Type of study Number of patients GI symptoms (%)
Azwar et al. [52] 2020 Case report 1 Epigastric pain, vomiting
Xu et al. [53] 2020 Retrospective case series 62 Diarrhea (8%)
Huang et al. [3] 2020 Prospective 41 Diarrhea (3%)
Pan et al. [54] 2020 Cross-sectional 204 Diarrhea (17%), vomiting (2%), abdominal pain (1%)
Jin et al. [58] 2020 Retrospective 651 Diarrhea (8.14%), nausea, vomiting
Zhang et al. [16] 2020 Retrospective 140 Nausea (17.3%), Diarrhea (12.9%), Anorexia (12.2%), Abdominal pain (5.8%),
Belching (5%), Emesis (5%)
Wang et al. [2] 2020 Retrospective case series 138 Diarrhea (10.1%), Nausea (10.1%), Vomiting (3.6%), Abdominal pain (2.2%)
Nobel et al. [63] 2020 Case-control 278 Diarrhea (61%), Nausea (58%)
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those with severe disease [5,10,43,89-91]. Patients with elevated creat-
inine at admissionweremore likely to be admitted to the ICU [4,91-93].
Patients who survive COVID-19-related AKI have been shown to be at
an increased risk of developing progressive CKD after the initial infec-
tion [86]. The risk CKD is associated with the severity of the AKI and
the presence or absence of tubular damage [94]. These results suggest
that early recognition of kidney dysfunction in patients with SARS-
CoV-2 is important for disposition and monitoring for potential decom-
pensation and to reduce the progression to chronic kidney impairment.
3.4.2. Acute Kidney Injury and mortality
In addition to being a predictor of severe disease, Li et al. demon-
strated that patients who developed an AKI had a 5.3-fold increased
risk of mortality compared to thosewithout kidney abnormalities, illus-
trating the importance of renal dysfunction as a negative prognostic
indicator for survival [87]. Chen et al. also determined that 25% of non-
survivors had developed an AKI during hospitalization [43]. One study
noted that the kidney was the third most commonly damaged organ
after the lungs and heart in those who died due to COVID-19 [89]. A
consecutive cohort study of 710 COVID-19 positive patients confirmed
thatmarkers of kidney dysfunction such as elevated BUN and creatinine
were independent risk factors for in-hospital death even after adjusting
for potential confounders [91]. Mortality for those who presented with
evidence of renal failure on admissionwas33.7% vs. 13.2% in thosewith-
out kidney dysfunction [91]. Similarly, Pei et al. demonstrated that pa-
tients with renal involvement had higher overall mortality compared to
those without (11.2% vs 1.2%) [88]. Patients with chronic kidney disease
are particularly vulnerable to negative outcomes.A recentmeta-analysis
confirmed that those with pre-existing renal dysfunction appeared to
have significantly higher pneumonia-relatedmortality than thosewith-
out underlying renal disease and are at increased risk for severe COVID-
19 infection [95,96].
When comparing SARS-CoV-2 with SARS-CoV, AKI was a much less
common finding (6%) during the 2003 outbreak of SARS, but it was rec-
ognized as a significant indicator ofmortality (92% of SARS patientswith
AKI died) [92]. Similarly, renal dysfunction was also associated with in-
creased risk of death in patients infected with H1N1 [93]. Evidence of
the prognostic implications of kidney injury in other serious respiratory
viruses highlights the importance of recognizing dysfunction early in
the disease course in order to improve morbidity and mortality. Early
recognition and treatment of renal dysfunction may help to improve
the prognosis of those infected with COVID-19.
3.5. Dermatologic symptoms
Based on a study of 1099 confirmed COVID-19 cases in Wuhan,
China, the most common symptoms included fever (43.8% of patients
were febrile on admission, and 88.7% of patients became febrile during
their hospital stay), cough (67.8%), and fatigue (38.1%). However, the
study did note that 2 patients (0.2%) had rashes but did elaborate fur-
ther [5]. There are severalmentions in the literature of the dermatologic
manifestations of SARS-CoV-2, but a predictable pattern has yet to
emerge in the research.
3.5.1. Cutaneous symptoms in COVID-19 patients
Dermatologists have become increasingly involved in caring for
COVID-19 patients due to shifting clinical responsibilities during the
pandemic, thus sparking an interest in the possible cutaneous manifes-
tations of SARS-CoV-2. Recalcati, an Italian dermatologist, looked at a
cohort of 88 COVID-19 positive patients and determined that 18
(20.4%) developed skin symptoms [97]. The manifestations reported
were erythematous rash (15.9%), generalized urticaria (3.41%) and
chicken pox-like lesions (1.14%) [97]. Dermatologists in Rome identified
2 of 130 patients with COVID-19 who presented with isolated
herpetiform lesions on their trunk during their inpatient stays [98]. A
patient in Barcelona exhibited vesicular lesions on her back 8 days
after COVID-19 diagnosis [98]. A multicenter case series of 22 patients
in Italy described a varicella-like exanthem as a specific cutaneousman-
ifestation of the virus [99]. Furthermore, the study showed that median
time from onset of systemic symptoms (fever, fatigue, or cough) to pre-
sentation of the exanthemwas 3 days with a median duration of 8 days
[99]. 54.5% of patients had vesicular lesions on the trunk, and the lesions
were scattered in themajority of cases (72.7%) [99]. 7 of the 22 patients
underwent skin biopsy and demonstrated histology consistent with
viral infection.
Several case reports have also described the potential skin manifes-
tations of COVID-19. A cluster of eight children in the U.K. presented
with features similar to atypical Kawasaki including the archetypal
skin rash appearance [100]. Following this report, additional cases
with similar presentation were observed across the globe. Henry et al.
outlined the case of a 27-year-old female who presented with pruritic
disseminated erythematous plaques without cough or fever. Two days
later she tested positive for COVID-19 after the onset of chest pain and
fever [101]. Another case report discussed a 28-year-old femalewhode-
veloped confluent “erythematous-yellowish” papules that progressed
to pruritic, hardened plaques 13 days after testing positive for COVID-
19 [102]. Joob and Wiwanitkit detailed the case of a petechial eruption
and thrombocytopenia initially thought to be Dengue fever, but ulti-
mately proven to be COVID-19 after the development of respiratory
symptoms [103]. Amatore et al. discussed a 39-year-old male who
complained of fever and exhibited “erythematous and edematous
non-pruritic annular fixed plaques involving the upper limbs, chest,
neck, abdomen and palms, sparing the face and mucous membranes”
without cough or dyspnea [104]. The patient was tested for and diag-
nosed with COVID-19 after reporting exposure to a family member
with the virus. Similarly, Van Damme et al. examined cases of dissemi-
nated urticaria in two febrile patients who later developed respiratory
symptoms and tested positive for COVID-19 [105].
3.5.2. Cutaneous reactions secondary to drug exposure
Dermatologists have been challenged with differentiating between
infectious and allergic etiologies of rashes associated with COVID-19,
since they are both clinically and histologically similar. Many of the
medication combinations currently under investigation for the treat-
ment of the virus may lead to drug eruptions [106]. In a study of 140
COVID-19patients by Zhang et al., drug hypersensitivity (11.4%) and ur-
ticaria (1.4%) were the most prevalent cutaneous symptoms associated
with the virus [16]. Jimenez-Cauhe et al. described a patient with
“erythemato-purpuric, millimetric, coalescing macules, located in flex-
ural regions” that developed 3 days into treatment with
hydroxychloroquine and lopinavir/ritonavir [107]. It was unclear
whether these lesions were a manifestation of SARS-CoV-2 or an ad-
verse reaction to the medications; however, there are no additional re-
ports of dermatological symptoms in patients treated with this
combination therapy [107]. Another report described sterile pustules,
similar to the typical findings of acute generalized exanthematous
pustulosis (AGEP), as a cutaneous manifestation of COVID-19 [108]. Al-
though AGEP is classically associated with drugs, it is possible that
COVID-19 can predispose certain patients to develop AGEP-like cutane-
ous eruptions as a late-onset manifestation of the infection.
3.5.3. Cutaneous reactions secondary to hypercoagulable states
In addition to potential drug hypersensitivity or direct viral infection
of the skin, Manalo et al. hypothesized that underlying DIC and
microthrombi may contribute to cutaneous symptoms [109]. The
study described two cases of unilateral transient livedo reticularis in
non-critically ill COVID-19 positive patients. Similarly, a retrospective
study of 7 critically ill patients in Wuhan, China exhibited significant
limb ischemia with plantar plaques and acral cyanosis as dermatologic
manifestations of their underlying hypercoagulable state [110].
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While the cutaneous manifestations of COVID-19 can vary, early
identification of unusual lesions in thosewithout a known trigger is cru-
cial to limiting the spread of COVID-19.
3.6. Neurologic symptoms
Recent studies have indicated that the SARS-CoV-2 is similar in tax-
onomy and sequence to the SARS-CoV virus [111]. The virus utilizes a
spike protein S1 to attach to the host membrane by interacting with
host ACE-2 receptor, which is found on neurons, endothelial cells, kid-
neys, lungs, and small intestine [112]. Upon entering the cell, it initiates
an immune cascadewhich stimulates CD4+ T cells, and this sequence of
events activates macrophages to produce IL-6, leading to a cytokine
storm and eventual systemic destruction of tissues [113]. There are sev-
eral neurological manifestations of the virus that are important to rec-
ognize and treat early.
3.6.1. The Nervous System & Respiratory Distress
The SARS-CoV-2 virus is known to cause severe respiratory distress
through direct invasion into the lung parenchyma as evidenced by the
destructive pattern seen on imaging of COVID-19 positive patients.
However, some patients with evidence of significant lung damage and
severe hypoxic do not develop tachypnea [114]. Scientists have hypoth-
esized that there is an abnormal response of the peripheral afferent fi-
bers in the lungs and airways that stimulate respiration [114]. Direct
entry of the virus into brain tissue, notably the brainstem, may also re-
sult in the loss of involuntary control of breathing [115,116].
3.6.2. Neurologic Manifestations
SARS-CoV-2 is believed to enter the nervous system via hematoge-
nous spread, directly through the cribriform plate, or through retro-
grade neuronal synapses from the olfactory bulb and vagal afferents
[111,113,117,118]. Upon entering the nervous system, it can manifest
as a viral encephalitis, cerebrovascular disease, or peripheral nerve
symptoms [117,119,120].
3.6.2.1. Viral Encephalitis. Various case reports summarized in Table 3
suggest that COVID-19 causes symptoms consistent with meningoen-
cephalitis [121-124]. Some COVID-19 positive patients presented with
alteredmental status and fever, and CSF studies showed elevated lym-
phocyte count but a negative viral biofire [121-124]. Though these pre-
sentations could not be definitively linked to the virus due to the lack of
CSFSARS-CoV-2 testingat the time,noother etiology for theviralmenin-
goencephalitis was found in this COVID-19 positive cohort. A study con-
ducted at the Beijing Ditan Hospital did confirm the presence of SARS-
CoV-2 in the cerebrospinal fluid of patients with known COVID-19 and
symptomsconsistentwithencephalitisbygenomesequencing[125].Ev-
idence of infectious toxic encephalitis was also found when cerebral
edema was identified during autopsy of COVID-19 patients [38]. A re-
cently published report detailed the case of serious neurologic damage
and mental abnormalities in a patient whose infection was confirmed
by IgM and IgG antibodies in the CSF despite negative nasopharyngeal
swabs.After the initialpresentationof fatigueandheadaches, thepatient
suddenly developed the inability towalk, uroclepsia, coprolalia, and de-
lusions. His CSF studies were strongly positive for SARS-CoV-2 antibod-
ies, and after weeks of antiviral and antipsychotic treatment, he was
dischargedwithmild hand tremors and fatigue [126].
3.6.3. Cerebrovascular disease
A large retrospective study of 221 patients with COVID-19 at the
Union hospital in Wuhan found that 5% of patients presented with
acute ischemic stroke, one patient developed cerebral venous sinus
thrombosis (CVST), and one had cerebral hemorrhage [127,128].
Those with cerebrovascular disease were significantly older (71·6 ±
15·7 years vs 52·1 ± 15·3 years; p < 0·05) and had cardiovascular
risk factors. Lab evaluation of this cohort determined that they were
more likely to have elevated CRP and d-dimer, lymphopenia, thrombo-
cytopenia, and uremia [127-129].
Cerebralhemorrhage is thought tobeaconsequenceof thevirusbind-
ing toACE-2 receptors onendothelium, contributing tobreakdownof the
blood brain barrier [117,120]. Ischemic changes and CVST are likely sec-
ondary to a hypercoagulable and pro-inflammatory state, further sup-
ported by elevation in CRP and d-dimer in these patients [117,128,129].
Numerous other studies summarized in Table 2 discuss presentations of
cerebrovascular disease in COVID-19 patients [120,128,129].
While it is theorized in many of the aforementioned studies that pa-
tientswhoare COVID-19positive are at increased risk for cerebral ische-
mia, research out of Piacenza, Italy noted decreased rates of admission
for stroke. They reported only 6 admissions for CVA from February 21,
2020 to March 25, 2020 compared to their normal monthly average of
approximately 51 cases [130]. The authors put forth a number of theo-
ries for these findings, such as thrombocytopenia or the potential neu-
roprotective role of IL-6. Research related to CVA incidence in the time
of COVID is currently mixed, and further studies need to be conducted
to corroborate these findings.
3.6.3.1. Seizures. Since many studies have demonstrated that COVID-19
patients are at increased risk for encephalopathy and cerebrovascular
disorders, it has been theorized that these clinical scenarios could lead
to seizures [127-129]. However, a large multi-center retrospective
study of 304 COVID-19 positive patients in China study evaluated sei-
zure activity in a cohort of patients with no prior history of epilepsy
[121]. Only two patients were identified as having seizure-like activity
despite the presence of potentially predisposing hypoxia or electrolyte
abnormalities in the majority of the cohort. Both patients were later
found to have severe electrolyte abnormalities, and symptoms im-
proved with correction [121]. A study of 111 COVID-19 patients within
the New York academic hospital system investigated EEG abnormalities
among infected patients. This study showed that themost frequent EEG
finding was generalized slowing (57%) and epileptiform findings were
observed in 30% and seizures in 7% (4% were non-convulsive seizures).
The study also concluded that only a history of epilepsy and definite
clinical seizures prior to EEG testing independently predicted epilepti-
form findings on EEG [131].
3.6.3.2. Peripheral nervous system. Though most research efforts have
been focused on identifying CNSdysfunction in SARS-CoV-2, some stud-
ies have discussed the effect on the peripheral nervous system. One case
series reported on a patient with COVID-19-related Miller-Fisher syn-
drome and another with polyneuritis cranialis. The first patient devel-
oped characteristic features with external ophthalmoplegia, ataxia, and
loss of tendon reflexes and recovered after being treated with IVIG
[132]. The second had ageusia, areflexia, and abducens palsy consistent
with polyneuritis cranialis, which spontaneously and rapidly improved
[132]. A large retrospective study byMao L et al. determined that 5% of
patients had hypogeusia and another 5% had hyposmia [129]. Several
Chinese studies indicated that up to 70% of patients complained ofmyal-
giaswith increases in creatine kinase (CK) present in up to 33%, suggest-
ing a possible SARS-CoV-2 viral myositis [2,3,28,124,133]. A recently
published report details the caseof acute transversemyelitis after a com-
plicated SARS-CoV-2 infection. The patient developed hypotonia in both
lower limbswithabsentdistal reflexes. AnMRIwithgadoliniumcontrast
showed increasedT2 signal betweenC7-T12withanLPsignificant for an
elevated IgG index and a positive RT-PCR for SARS-CoV-2. He recovered
oneweek later after treatmentwith IVIG [134].
3.7. Psychiatric symptoms
With the rise of COVID-19 cases in theUS, social distancingmeasures
have continued significantly past their predicted duration, likely con-
tributing to increased anxiety, depression, and loneliness. Prior epi-
demics have negatively impacted the psychological health of the
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population. A prospective study conducted during the 2003 SARS epi-
demic in Hong Kong demonstrated that stress, dysphoria, impaired
sleep and concentration were much greater among infected individuals
than controls, and 25% of the patients requested follow-up for the neg-
ative psychological effects of being infected [135]. A study examining
psychiatric symptoms in SARS survivors one year later indicated that
these patients experienced persistent distress with 64% scoring above
the GHQ12 threshold for psychiatric morbidity [136]. Additionally, in-
fected healthcare workers who survived showed significantly higher
stress levels, more depression, and symptoms consistent with PTSD
[136]. Based on this research, it is possible we will see similar patterns
of anxiety, depression and other psychiatric symptoms in those cur-
rently affected by COVID-19.
3.7.1. Cause of psychiatric symptoms
The psychological impact of this pandemic is likely multifacto-
rial, due in parts to self-isolation, fear of infection, uncertainty, fi-
nancial woes, job insecurity, and pre-existing mental health
conditions. A recent study out of China using online surveys deter-
mined that 16.5% of respondents exhibited moderate to severe de-
pressive symptoms, and 28.8% reported severe anxiety [137]. Of
these respondents, 75.2% attributed their increased anxiety to
fear that they or their family members could contract COVID-19
[137]. Misinformation and uncertainly can raise anxiety levels in
both healthy individuals and those with preexisting psychiatric
conditions [138]. Lunn et al. observed that the absence of effective
disease treatment and the uncertainty regarding outcomes for
those infected has led to mass panic and anxiety [139]. In addition,
the rapid spread of misinformation and bias has induced fear, prej-
udice, and xenophobia [140,141].
3.7.2. Social isolation and mental health
One of the major consequences of the pandemic is increased
social isolation, a risk factor that is strongly associated with de-
pression, self-harm, and suicide [142-144]. Older adults are espe-
cially vulnerable to the mental health ramifications of social
isolation, particularly those in residential care [145]. Mental health
experts have stressed the importance of research examining the
rates of anxiety, depression, and other psychiatric symptoms to in-
form interventions during this public health crisis [142]. An analy-
sis of emotional indicators on the Chinese social media platform
Weibo during the height of their COVID-19 crisis demonstrated
Table 3
Studies with COVID-19 patients presenting with neurologic symptoms.
Study (locations, date) Methods Number of Patients Neurologic Manifestations (% of
patients)
Lab Abnormalities
Mao L, et al. (Wuhan China,
2020) [129]












count, lower platelet count
and higher BUN
PNS: Higher CK
Li, Y. et al. (Wuhan, China 2020)
[128]




Elevated CRP and D Dimer:
C-reaction protein
Lu, L et al. (Hubei, Sichuan, and







Gutiérrez-Ortiz C, et al. (Madrid,
Spain 2020) [132]




Duong L, et al.
(Los Angeles, USA, 2020) [122]
Case Report 1 Meningoencephalitis CSF: High lymphocyte count,
protein elevated and glucose
was normal. Negative HSV
PCR
Yin R, et al. (Wuhan, China,
2019) [123]
Case Report 1 Encephalitis Lymphocyte count:
3.3 × 109/L and C-reactive
protein (CRP) level,
10.74 mg/L
Zhang J et al. (Wuhan, China
2020) [124]







Huang C et al. (Wuhan, China
2019) [3]





Elevated D dimer, Elevated
LFTs, normal procalcitonin
Wang et al. (Wuhan, China
2020) [2]





Yang X et al. (Wuhan, China
2020) [28]
Retrospective Analysis 52 Headache (6%)
PNS: Myalgia (10%)
Low lymphocyte count
Chen N et al. (Wuhan, China
2020) [4]
Retrospective Analysis 99 Confusion (9%) Headache (8%) Low Lymphocyte count, Low
platelets, Low hemoglobin,
Increased LDH, Increased D
dimer, Increased CRP
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that anxiety and depression increased while positive emotional in-
dicators (Oxford happiness) decreased [146]. The study also ana-
lyzed linguistic expression and determined that there was an
increase in the use of the words “health” and “family” and a de-
crease in “leisure” and “friend”, highlighting the rapidly evolving
priorities in this population during the pandemic [146].
Patients with pre-existing mental health conditions are both
more vulnerable to the psychological impacts of the pandemic
and at increased risk of infection, likely due to cognitive impair-
ment, diminished efforts for personal protection, lack of awareness
of their personal risk, and discrimination [147]. Patients with se-
vere mental illness are also more vulnerable due to significantly
higher rates of both homelessness and smoking [148]. Many pa-
tients have reported poor adherence to medication during this
time, disruption of mental health services, and suspension of sub-
stance abuse treatment [149]. Lastly, the close proximity with
which many homeless patients with mental illness live is a signif-
icant risk factor for the spread of the virus.
3.7.3. Psychiatric Manifestations of COVID-19 Infection
There is some emerging research that suggests a link between
COVID-19 infection and severe psychiatric symptoms. A cross-
sectional study of 112 patients with COVID-19 reported higher
levels of somatization, depression, anxiety, phobias, sleep distur-
bances, and eating disorders in infected patients compared to the
healthy population [150]. Case reports have detailed the psychiat-
ric presentations of patients with SARS-CoV-2 both during their
acute infections and post- clinical recovery. One such patient pre-
sented to the hospital with extreme anxiety, suicidal ideation, ag-
itation, and hallucination [151]. A case series out of Spain
examined viral involvement in new-onset psychiatric symptoms.
They discussed several patients who presented to the hospital
with psychosis and concomitant infection with SARS-CoV-2 with-
out any known history of prior mental health disorders [ 152].
While neither of these reports was able to establish whether the
patients' psychoses were primary or secondary (related to treat-
ment or acute delirium), these findings suggest the need for addi-
tional research on the neuropsychiatric manifestations of COVID-
19 infection.
Effective management of mental health problems during the
pandemic has proven challenging, especially as infectious concerns
inhibit face to face evaluation, and the influx of COVID-19 cases
has consumed healthcare resources. The rapid spread of infection
has led to increased rates of depression, anxiety, and feelings of
self-isolation within the community. Additionally, some evidence
suggests that COVID-19 can present with primary or secondary
psychiatric symptoms. More research needs to be performed to
fully assess the mental health burden of this crisis, particularly
with regard to vulnerable populations.
4. Conclusions
The COVID-19 pandemic has resulted in massive, widespread eco-
nomic and public health hardships. While several therapies are still
under investigation, there remains no definitive treatment for SARS-
CoV-2. Many clinical trials are ongoing, and treatment of COVID-19 cur-
rently includes supportive care and symptomatic management.
Community-wide public health containment strategies consist of social
isolation, distancing, face coverings, and travel restrictions. Despite
these efforts, the virus continues to spread, highlighting an even greater
need for additional research into the pathophysiology, clinical presenta-
tions, and treatment modalities for SARS-CoV-2. Ultimately, it is critical
for frontline healthcare workers to understand and recognize themany
clinical manifestations of COVID-19 in order to better protect them-
selves, efficiently identify potentially infected patients, and prevent nos-
ocomial outbreaks.
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